Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR 97006, USA.
Trends Endocrinol Metab. 2010 Mar;21(3):190-7. doi: 10.1016/j.tem.2009.11.003. Epub 2009 Dec 11.
G protein-coupled receptors (GPCRs) are among the most common potential targets for pharmacological design. Synthesized in the endoplasmic reticulum, they interact with endogenous chaperones that assist in folding (or can retain incorrectly folded proteins) and are transferred to the plasma membrane where they exert their physiological functions. We summarize trafficking of the gonadotropin-releasing hormone receptor (GnRHR) to the plasma membrane. The trafficking of GnRHR is among the best characterized due in part to its small size and the consequent ease of making mutant proteins. Human mutations that cause disease through the misrouting of GPCRs including GnRHR are also reviewed. Special emphasis is placed on therapeutic opportunities presented by pharmacological chaperone drugs, or pharmacoperones, that allow misrouted mutants to be routed correctly and restored to function.
G 蛋白偶联受体(GPCRs)是药理学设计中最常见的潜在靶点之一。它们在内质网中合成,与内源性伴侣蛋白相互作用,伴侣蛋白有助于折叠(或可以保留错误折叠的蛋白质),并被转移到质膜,在那里它们发挥生理功能。我们总结了促性腺激素释放激素受体(GnRHR)向质膜的运输。GnRHR 的运输是最具特征性的,部分原因是其体积小,因此很容易制造突变蛋白。我们还回顾了导致疾病的人类突变,这些突变通过 GPCR 包括 GnRHR 的错误途径发生。特别强调了药理学伴侣药物或药理学配体药物带来的治疗机会,这些药物可以使错误途径的突变体正确途径,并恢复功能。